Skip to content

Lineage Cell Therapeutics, Inc.

LCTX

CIK 0000876343

← back to feed
Revenue (TTM)
$9.67M
+53.2% YoY Q1 May 2026
Net Income (TTM)
−$69.2M
−241.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.31
−211.1% YoY Q1 May 2026
Gross Margin
95.2%
Q1 May 2026
Operating Margin
-389.4%
Q1 May 2026
Net Margin
-715.4%
Q1 May 2026
Free Cash Flow (TTM)
−$30.37M
Q1 May 2026
Cash
$35.94M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
249.3M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings